Morgan Stanley Raises Price Target for Alnylam

Despite a positive headline, ALNY stock has fallen 21.8% in the last 24 hours, with technical indicators showing a weak outlook. While the RSI at 35.6 approaches oversold territory, the MACD continues to give a sell signal, and the price is trading below both the 20-day and 50-day moving averages. Although Morgan Stanley's target price increase offers hope for a short-term recovery, the current technical structure and volatility following the sharp decline keep direction uncertain. Therefore, rather than expecting a clear short-term trend, the price is more likely to find balance through consolidation or a slight rebound.

Morgan Stanley's upward revision of its price target for Alnylam could be interpreted as a positive signal for the pharmaceutical sector and may provide indirect support for MS stock. Technical indicators also back this optimistic outlook: the RSI at 62.8 is not approaching overbought territory, the MACD line remains above the signal line, and upward momentum is sustained. The stock is trading above its 20-day and 50-day moving averages and has gained 1.42% in the last 24 hours. However, since the news is not directly related to MS and amid broader market uncertainties, the upside potential remains limited.